Discover
QNCX
Quince Therapeutics, Inc.
16.75
2 x 12.96
2 x 19.78
bid
ask
-
0.95
5.37%
2 @ 04:00 PM
16.97 +0.22 (1.31%)
| Ytd | -50.00% | |
| 1y | 10.20% |
15.10
day range
18.00
15.10
52 week range
910.00
| Open | 18.00 | Prev Close | 17.70 | Low | 15.10 | High | 18.00 | Mkt Cap | 16.38M |
| Vol | 103.36K | Avg Vol | 231.82K | EPS | -210.00 | P/E | N/A | Forward P/E | -5.68 |
| Beta | 0.71 | Short Ratio | 2.27 | Inst. Own | 25.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 22.11 | 200-d Avg | 248.82 | 1yr Est | 9.00 |
QNCX News
globenewswire.com
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QN
benzinga.com
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price T
Leerink Partners analyst Joseph Schwartz initiates coverage on Quince Therapeutics (NASDAQ:QNCX)
benzinga.com
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDA